Treatment Strategies & Interventions
At a Glance
Treatment for superficial siderosis focuses first on finding and stopping the ongoing bleed, often by repairing a tear in the spinal lining. Deferiprone may be considered in selected cases, but it is off-label, not routine, and requires strict blood-count monitoring.
The treatment of superficial siderosis is focused on two main goals: stopping the bleed that is causing the damage and, in some cases, attempting to remove the iron that has already settled on the brain. Because this is a rare and complex condition, treatment must be highly individualized and managed by a specialized team [1].
(Note: If you have Cortical Superficial Siderosis (cSS), your management focuses on stroke prevention, blood pressure control, and individualized antithrombotic decisions, rather than the spinal repair and chelation discussed here.)
Stopping the Source: The First Priority
For most patients with classical (infratentorial) superficial siderosis, the primary medical approach is to find and fix the source of the bleeding [1][2]. This is because as long as blood continues to seep into the spinal fluid, the damage will likely continue to progress.
- Surgical Repair: If a dural defect (a tear in the spinal lining) or another operable source is found, surgery is often considered to close the hole or remove the bleeding lesion [3].
- What to Expect: It is important to have realistic expectations. Surgery is primarily a stabilization treatment. In a retrospective review of 38 surgically treated patients with spinal dural defects, about 66% saw their condition stabilize (stop getting worse) and 21% saw some clinical improvement, while 13.2% deteriorated [3]. These percentages are from a small observational study, so they do not guarantee an individual outcome.
- The Role of Timing: Earlier treatment generally aims to preserve function. Research in small cohorts suggests that patients who have surgery within a year of noticing symptoms may be more likely to see improvement, but evaluation is still worthwhile for long-standing symptoms; established neurological damage—especially hearing loss—is often permanent and may not reverse even after the bleed is stopped [4][5][6].
- Risks: Surgery carries its own risks, including recurrent CSF leaks, infection, neurological injury, and the possibility that the procedure may fail to stop the disease progression.
Removing the Iron: Chelation Therapy
In cases where the source of the bleed cannot be found or repaired, or if the disease continues to progress after surgery, doctors may consider iron chelation therapy. This involves using a medication called deferiprone to try and “pull” the iron out of the brain tissue [7].
- Experimental Status: Deferiprone is currently considered an “off-label” or experimental treatment for superficial siderosis. While some small studies have shown it can reduce iron levels on MRIs and stabilize symptoms in some patients, the evidence is not yet strong enough for it to be a routine recommendation for everyone [7][8].
- The Primary Rule: Treating the MRI findings (the iron) with chelators before looking for the source of the bleed is generally not recommended. The source should always be investigated first if possible [1].
Serious Safety Risks of Deferiprone
If you and your doctor decide to try deferiprone, you must be aware of its potential for severe side effects. The most serious concern is a drop in white blood cells, specifically neutropenia (low levels of neutrophils) and agranulocytosis (a severe, life-threatening lack of white blood cells) [7][9].
- Strict Monitoring: You must follow a strict blood-monitoring protocol set by your specialist—frequently an Absolute Neutrophil Count (ANC) test every single week early in treatment [8][9]. You must never skip monitoring. The goal is to catch a drop in white blood cells before it turns into a dangerous infection.
- Neutropenic Sepsis: Without white blood cells, the body cannot fight infection. This can lead to neutropenic sepsis, a medical emergency that can be fatal if not treated immediately with intravenous antibiotics [10][11].
- The “Fever Rule”: If you are on deferiprone and develop a fever, severe sore throat, or any other sign of infection, you must seek medical attention immediately—do not wait for your next scheduled blood test [11].
Practical Symptom Management
If an operable source is not found, or while you are waiting for a procedure, practical symptom management is critical. This includes optimizing hearing aids, pursuing physical therapy for balance and fall prevention, and discussing medications for nerve pain or spasticity with your neurologist.
Common questions in this guide
What is the first treatment priority for superficial siderosis?
Can surgery improve symptoms caused by superficial siderosis?
When might deferiprone be considered for superficial siderosis?
What blood tests are needed with deferiprone?
What should I do if I get a fever while taking deferiprone?
What therapies can help with daily symptoms of superficial siderosis?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Superficial siderosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Have we confirmed the exact location of the bleeding source, and is it a candidate for surgical repair?
- 2.What are the specific risks (e.g., recurrent leak, infection) versus benefits of surgery in my specific case?
- 3.If we consider deferiprone, what is your exact protocol for the required blood count monitoring?
- 4.What specific 'red flag' symptoms (like a fever) should I watch for while taking an iron chelator?
- 5.What practical therapies (like vestibular rehab or audiology) should we start now to manage my daily symptoms?
References
References (11)
- 1
Superficial Siderosis: A Clinical Review.
Kumar N
Annals of neurology 2021; (89(6)):1068-1079 doi:10.1002/ana.26083.
PMID: 33860558 - 2
Infratentorial superficial siderosis: Classification, diagnostic criteria, and rational investigation pathway.
Wilson D, Chatterjee F, Farmer SF, et al.
Annals of neurology 2017; (81(3)):333-343 doi:10.1002/ana.24850.
PMID: 28019651 - 3
Safety and effectiveness of spinal dural defect repair in the management of superficial siderosis: A systematic review and patient-level analysis.
Mariajoseph FP, Castle-Kirszbaum M, Chandra RV, et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2023; (109()):44-49 doi:10.1016/j.jocn.2023.01.011.
PMID: 36731382 - 4
Surgical closure of spinal cerebrospinal fluid leaks improves symptoms in patients with superficial siderosis.
El Rahal A, Haupt B, Fung C, et al.
European journal of neurology 2024; (31(3)):e16122 doi:10.1111/ene.16122.
PMID: 38015455 - 5
[Superficial Siderosis].
Ohira M, Takao M
Brain and nerve = Shinkei kenkyu no shinpo 2018; (70(10)):1107-1113 doi:10.11477/mf.1416201143.
PMID: 30287696 - 6
Audiological Progression and Treatment Outcomes in Superficial Siderosis: A 10-Year Retrospective Review of 46 Patients.
Nishio A, Kawashima Y, Takeda T, et al.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2025; (46(8)):895-902 doi:10.1097/MAO.0000000000004535.
PMID: 40570319 - 7
Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review.
Flores Martin A, Shanmugarajah P, Hoggard N, Hadjivassiliou M
Cerebellum (London, England) 2021; (20(3)):454-461 doi:10.1007/s12311-020-01222-7.
PMID: 33409768 - 8
Two-year observational study of deferiprone in superficial siderosis.
Kessler RA, Li X, Schwartz K, et al.
CNS neuroscience & therapeutics 2018; (24(3)):187-192 doi:10.1111/cns.12792.
PMID: 29285884 - 9
Deferiprone-induced agranulocytosis: 20 years of clinical observations.
Tricta F, Uetrecht J, Galanello R, et al.
American journal of hematology 2016; (91(10)):1026-31 doi:10.1002/ajh.24479.
PMID: 27415835 - 10
Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis.
Sammaraiee Y, Banerjee G, Farmer S, et al.
Journal of neurology 2020; (267(1)):239-243 doi:10.1007/s00415-019-09577-6.
PMID: 31620867 - 11
A Case of Fatal Agranulocytosis That Developed in a Patient with β-Thalassemia Major Treated with Deferiprone.
Mainou M, Kotsiafti A, Klonizakis P, et al.
Hemoglobin 2016; (40(6)):435-437 doi:10.1080/03630269.2016.1276929.
PMID: 28361596
This page is for informational purposes only and does not constitute medical advice. A specialist team should guide decisions about bleeding-source repair, deferiprone, blood-count monitoring, and symptom care.